Search

Meeting Coverage:

Retina World Congress Meeting

RWC: 2017

Abicipar Pegol in Phase 2

Pravin Dugel, MD

Show Description +

Pravin Dugel, MD, summarizes his presentation on the phase 2 REACH study comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for treatment of wet age-related macular degeneration.

Posted: 1/25/2017

Keywords:

Wet AMD

Up Next

OCTA in DR

Nadia Waheed, MD

Managing TRDs

Maria H. Berrocal, MD

Diagnosis and Treatment of FEVR

Diagnosis and Treatment of FEVR

Ehab El-Rayes, MD

Widefield Imaging and OCT

Widefield Imaging and OCT

Netan Choudhry, MD

Anti-VEGF Therapy and Vitrectomy in Severe PDR

Anti-VEGF Therapy and Vitrectomy in Severe PDR

Peeling ERM in Patients With Good Vision

Peeling ERM in Patients With Good Vision

Andre Gomes, MD

Welcome to the Retina World Congress!

Welcome to the Retina World Congress!

Rishi P. Singh, MD

How Long-Term RVO Patients Respond to Therapy

How Long-Term RVO Patients Respond to Therapy

Antonio Casella, MD, PhD

Early Intervention in PDR and Vitreous Hemorrhage

Early Intervention in PDR and Vitreous Hemorrhage

Francesco Boscia, MD

Multimodal Imaging in Ocular Oncology

Multimodal Imaging in Ocular Oncology

Prithvi Mruthyunjaya, MD

Back to All Videos

Abicipar Pegol in Phase 2

Pravin Dugel, MD

Pravin Dugel, MD, summarizes his presentation on the phase 2 REACH study comparing abicipar pegol (Allergan) with ranibizumab (Lucentis, Genentech) for treatment of wet age-related macular degeneration.

Posted: 1/25/2017

Keywords:

Wet AMD

Please log in to leave a comment.

More From RWC: 2017 Coverage

OCTA in DR

OCTA in DR

Nadia Waheed, MD

Managing TRDs

Managing TRDs

Maria H. Berrocal, MD

Diagnosis and Treatment of FEVR

Diagnosis and Treatment of FEVR

Ehab El-Rayes, MD

Widefield Imaging and OCT

Widefield Imaging and OCT

Netan Choudhry, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of RWC: 2017.